LILRA6

Across TCGA pan-cancer cohorts, LILRA6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LILRA6 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LILRA6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LILRA6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and LUAD are the cancer types where LILRA6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.806	0.568	.043	2	view →
LUAD	DFS	Tertile	All	0.664	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LILRA6–LSCC (DFS)

Open the LSCC breakdown →